单中心回顾性评价dupilumab诱导的澳大利亚成人中至重度特应性皮炎眼表疾病。

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2024-12-16 DOI:10.1111/ajd.14400

Alexis Arasu, Andrew Awad, Vanessa Tran, Gayle Ross

{"title":"单中心回顾性评价dupilumab诱导的澳大利亚成人中至重度特应性皮炎眼表疾病。","authors":"Alexis Arasu, Andrew Awad, Vanessa Tran, Gayle Ross","doi":"10.1111/ajd.14400","DOIUrl":null,"url":null,"abstract":"<p>Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"e24-e27"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Single-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis\",\"authors\":\"Alexis Arasu, Andrew Awad, Vanessa Tran, Gayle Ross\",\"doi\":\"10.1111/ajd.14400\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.</p>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\"66 1\",\"pages\":\"e24-e27\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14400\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14400","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

特应性皮炎患者的治疗和管理结果随着dupilumab作为一种安全有效的治疗方法纳入药物获益方案而显著改善。眼表疾病仍然是dupilumab最常见的不良事件之一，影响生活质量并可能中断治疗。本回顾性研究旨在进一步描述dupilumab诱导的眼表疾病的经历和危险因素，为管理提供信息，并支持患者的长期使用，改善总体治疗结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Single-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis

Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.